Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Japan Approves Lagevrio, Korea Clears Paxlovid

Plus, Boosters In Japan, Further Vaccine Progress In Korea

Executive Summary

Oral antivirals make progress in Asia as Japan issues emergency approval to Merck's Lagevrio in a matter of weeks and South Korea clears Pfizer's contender Paxlovid. Vaccines also move forward in both countries with deals for boosters, new supply agreements and the advancement of home-grown candidates.  

You may also be interested in...



Coronavirus Update: Generics And Hurdles For Molnupiravir, More Japan Approvals

More generic deals but also US approval hurdles for Merck's oral antiviral, while Japan approves more options and Valneva's vaccine candidate shows promise against Omicron. 

Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid

More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine. 

Wave Of Molnupiravir Generics In India Amid Early Physician Cheer

India authorizes molnupiravir for restricted emergency use in COVID-19, marking the arrival of around a dozen “affordable” generics of  Merck & Co. and Ridgeback Biotherapeutics' oral antiviral. Physicians say data are “pretty compelling” notwithstanding the narrow FDA nod.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel